Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05243719 · ClinicalTrials.gov registry record · Phase 1
Open-label Extension Study of ADP101
A Phase 1 study, sponsored by Alladapt Immunotherapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT05243719 is a Phase 1 study that was terminated before completion, run by Alladapt Immunotherapeutics. The registered enrollment target is 45 participants.
The verdict
NCT05243719, a Phase 1 study, was terminated before completion, sponsored by Alladapt Immunotherapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is an open-label, safety extension study for participants who participated in the Harmony study (protocol ADP101-MA-01).
Interventions
- BIOLOGICAL ADP101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2024-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05243719
The ClinicalTrials.gov registry entry for NCT05243719 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alladapt Immunotherapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADP101 is the first listed.
NCT05243719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05243719 about?
NCT05243719 is a clinical study titled "Open-label Extension Study of ADP101". This is an open-label, safety extension study for participants who participated in the Harmony study (protocol ADP101-MA-01).
What is the current status of trial NCT05243719?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2022-03-14. Estimated completion is 2024-02-27.
What interventions are being tested in trial NCT05243719?
The interventions under investigation include: ADP101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05243719?
This trial is sponsored by Alladapt Immunotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.